Nooglutyl

Nooglutyl is an experimental nootropic discussed for brief focus and memory benefits, alongside fatigue, anxiety and sleep costs. Reports cannot establish effectiveness or safety.

What Nooglutyl is

• An experimental cognitive compound. Nooglutyl, also spelled Nooglutil, is N-(5-hydroxynicotinoyl)-L-glutamic acid. Community interest centers on memory and staying organized during work or study; the name should not be confused with Noopept. Official context Animal context
• The calcium salt needs its own context. Ampasse is the calcium salt of the same acid. Its intravenous clinical research is relevant background, but it cannot establish what an unverified powder does when swallowed or held under the tongue. Official context Official context
• AMPA is the research link. AMPA receptors help carry excitatory glutamate signals in the brain. Animal papers describe Nooglutyl as a positive modulator, and a rat-brain assay found receptor binding; that gives a research rationale, not proof of cognitive benefit in people. Animal context Animal context

What people report

• Clearer organization more than effortless wakefulness. The detailed accounts describe easier task organization. Feeling focused is not a measured gain in learning. Personal report
• Memory comparisons are subjective. Clear_vision described more stimulation and similar memory benefit after replacing coluracetam with Nooglutyl in a discussion involving PRL. The report does not isolate Nooglutyl or provide its amount. Personal report

How people compare it

• Noopept feels different. Self-Hacked favored Noopept for visual/long-term memory and Nooglutyl for connecting information; this is personal preference. Personal report
• Modafinil: not the same wakefulness experience. The shift reviewer did not find reliable wakefulness despite stimulation. Personal report
• Coluracetam and sunifiram: separate compounds. Commenters compare their cognitive impressions with Nooglutyl, but neither account supplies a reliable equivalence in dose, mechanism or safety. Personal report Personal report

Doses people discuss

• Estimated 10–15 mg and 20 mg in the shift review. The shift author initially used sublingual powder but lacked an accurate scale. A first heading says about 5 mg while its sentence says attempted 10 mg; later route is not restated. These estimates are not a standard range. Personal report
• 10–20 mg per use, up to 40 mg/day, in another report. Self-Hacked described a 5 mg first trial, then those first-week amounts. Later they reported 20–25 mg per use, no more than 30 mg at once or 60 mg/day, as effects faded; route was unspecified. This describes escalation, not safe ceilings. Personal report
• Other compounds’ amounts are not Nooglutyl doses. The coluracetam comparison includes milligrams for coluracetam and PRL but none for Nooglutyl. Neither those numbers nor animal mg/kg findings should fill that gap. Personal report

Half-life

• Human elimination timing remains unestablished here. These accounts describe sensations, not blood measurements. A few hours of focus cannot tell us when half the substance has left the body. Personal report

Onset

• About 30 minutes in one account. Self-Hacked reported energy and clarity; route unspecified. Personal report

Duration

• 2–3 hours in a separate comment. FusePods said Nooglutyl’s effects faded within that interval. No amount or route was supplied, so this is a personal felt window. Personal report
• 3–5 hours in one account. Self-Hacked described that duration with fatigue afterward. Personal report
• Fatigue around four hours into a work shift. The shift reviewer described roughly two further hours of tiredness. Useful focus and the end of unwanted effects are different endpoints. Personal report

Repeated use and breaks

• Two weeks with perceived tolerance. Self-Hacked increased amounts as effects weakened; no reset interval was established. Personal report
• A few days between trials in the shift review. The reviewer’s few-day breaks and impression of little addictive pull cannot establish freedom from dependence. Personal report
• A sunifiram timeline must stay with sunifiram. FusePods described waning benefit after a month of daily sunifiram, not a month-long Nooglutyl course. The comment cannot support a Nooglutyl cycling schedule. Personal report

What can outweigh the benefit

• Anxiety, chewing and a pronounced crash. The shift reviewer reported these problems, rising anxiety with higher amounts, diminishing benefit, and failed redosing for an all-nighter. Personal report
• Agitation and sleep disruption. Self-Hacked reported agitation and bedtime sleep disruption despite brief useful effects. Personal report
• A stacking warning is not an established interaction rule. Clear_vision warned about headaches from combining supposed AMPA modulators. The comment does not clearly document experiencing that combination, so the warning remains opinion rather than a measured risk or a reason to add another compound. Personal report
• A small trial leaves major safety questions. The available human trial cannot establish long-term safety, uncommon risks or the effects of medication combinations. Its formulation, route and patient population differ from the community reports. Official context

What the community accounts add

• The work setting changes the interpretation. Initial testing used no other aids; later sessions involved caffeine, an energy drink, 600 mg/day alpha-GPC and high-stimulant pre-workout. Early effects were mild; gym improvements were unimpressive. Personal report
• Later combinations weaken attribution. Self-Hacked combined coffee and later PRL-8-53/IDRA-21, and found coffee eased the fatigue. A possible hangover-anxiety improvement was explicitly considered placebo. Personal report
• A favorable comparison is still an individual report. Clear_vision’s account supplies a useful comparison with coluracetam, but no controlled change or memory testing. Its confident tone does not create evidence for a combination. Personal report
• The short reports leave practical gaps. FusePods supplies an additional short-duration observation but no dose or route. Different usernames widen the account set; they do not establish a representative sample, a response rate or agreement on a regimen. Personal report
• Withdrawal claims begin with animal work. A 2020 discussion asks about benzodiazepine and phenibut applications while linking a rat paper. It supplies no firsthand withdrawal outcome. The underlying experiment measured rat anxiety after diazepam withdrawal, not successful human detoxification. Reddit Animal context

What the research can and cannot add

• Human research exists for IV Ampasse. A 2021 randomized placebo-controlled study enrolled 124 people with chronic cerebrovascular disorders. It reported better cognitive-test outcomes after a 15-day IV treatment course; it did not test healthy people using community powders. Official context Official context
• Short-term tolerability is not a blanket safety finding. The abstract reports adverse events in 14.52% of the Ampasse group and 8.06% of placebo recipients, with no statistically significant difference. That result cannot exclude uncommon harms or establish safety for other routes or prolonged use. Official context
• The half-life figures belong to animal calcium-salt research. A 2010 bolus-administration study reported elimination half-lives of 0.73 hours in rats and 2.3 hours in rabbits. Its four-hour human figure was calculated by scaling between species, not measured in people; none establishes human oral or sublingual clearance. Animal context
• Binding strength is not a memory score. The rat-brain experiment reported an IC50 of 6.4 micromolar for Nooglutil versus 80 micromolar for Noopept. These are laboratory concentrations, not doses or a claim that one improves human memory by that ratio. Animal context